Muscle Structure Influences Utrophin Expression in Mice

1. MendellJR, ShillingC, LeslieND, FlaniganKM, al-DahhakR, et al. (2012) Evidence-based path to newborn screening for Duchenne muscular dystrophy. Ann Neurol 71: 304–313.

2. HoffmanEP, BrownRHJr, KunkelLM (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919–928.

3. KoenigM, HoffmanEP, BertelsonCJ, MonacoAP, FeenerC, et al. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50: 509–517.

4. BhasinN, LawR, LiaoG, SaferD, EllmerJ, et al. (2005) Molecular extensibility of mini-dystrophins and a dystrophin rod construct. J Mol Biol 352: 795–806.

5. MirzaA, SagathevanM, SahniN, ChoiL, MenhartN (2010) A biophysical map of the dystrophin rod. Biochim Biophys Acta 1804: 1796–1809.

6. HendersonDM, LeeA, ErvastiJM (2010) Disease-causing missense mutations in actin binding domain 1 of dystrophin induce thermodynamic instability and protein aggregation. Proc Natl Acad Sci U S A 107: 9632–9637.

7. ErvastiJM, SonnemannKJ (2008) Biology of the striated muscle dystrophin-glycoprotein complex. Int Rev Cytol 265: 191–225.

8. ErvastiJM, CampbellKP (1991) Membrane organization of the dystrophin-glycoprotein complex. Cell 66: 1121–1131.

9. KoenigM, KunkelLM (1990) Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility. J Biol Chem 265: 4560–4566.

10. ErvastiJM, OhlendieckK, KahlSD, GaverMG, CampbellKP (1990) Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345: 315–319.

11. ErvastiJM (2007) Dystrophin, its interactions with other proteins, and implications for muscular dystrophy. Biochim Biophys Acta 1772: 108–117.

12. KobayashiYM, RaderEP, CrawfordRW, IyengarNK, ThedensDR, et al. (2008) Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature 456: 511–515.

13. GradyRM, GrangeRW, LauKS, MaimoneMM, NicholMC, et al. (1999) Role for alpha-dystrobrevin in the pathogenesis of dystrophin-dependent muscular dystrophies. Nat Cell Biol 1: 215–220.

14. BrooksSV (1998) Rapid recovery following contraction-induced injury to in situ skeletal muscles in mdx mice. J Muscle Res Cell Motil 19: 179–187.

15. DellorussoC, CrawfordRW, ChamberlainJS, BrooksSV (2001) Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. J Muscle Res Cell Motil 22: 467–475.

16. FaulknerJA, NgR, DavisCS, LiS, ChamberlainJS (2008) Diaphragm muscle strip preparation for evaluation of gene therapies in mdx mice. Clin Exp Pharmacol Physiol 35: 725–729.

17. MoensP, BaatsenPH, MarechalG (1993) Increased susceptibility of EDL muscles from mdx mice to damage induced by contractions with stretch. J Muscle Res Cell Motil 14: 446–451.

18. PetrofBJ, ShragerJB, StedmanHH, KellyAM, SweeneyHL (1993) Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci U S A 90: 3710–3714.

19. BanksGB, ChamberlainJS (2008) The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Curr Top Dev Biol 84: 431–453.

20. LoveDR, HillDF, DicksonG, SpurrNK, BythBC, et al. (1989) An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 339: 55–58.

21. KhuranaTS, WatkinsSC, ChafeyP, ChellyJ, TomeFM, et al. (1991) Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscul Disord 1: 185–194.

22. PonsF, NicholsonLV, RobertA, VoitT, LegerJJ (1993) Dystrophin and dystrophin-related protein (utrophin) distribution in normal and dystrophin-deficient skeletal muscles. Neuromuscul Disord 3: 507–514.

23. DeconinckAE, RafaelJA, SkinnerJA, BrownSC, PotterAC, et al. (1997) Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 90: 717–727.

24. GradyRM, TengH, NicholMC, CunninghamJC, WilkinsonRS, et al. (1997) Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. Cell 90: 729–738.

25. ChevronMP, EchenneB, DemailleJ (1994) Absence of dystrophin and utrophin in a boy with severe muscular dystrophy. N Engl J Med 331: 1162–1163.

26. TinsleyJ, DeconinckN, FisherR, KahnD, PhelpsS, et al. (1998) Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4: 1441–1444.

27. KarpatiG, CarpenterS, MorrisGE, DaviesKE, GuerinC, et al. (1993) Localization and quantitation of the chromosome 6-encoded dystrophin-related protein in normal and pathological human muscle. J Neuropathol Exp Neurol 52: 119–128.

28. MizunoY, NonakaI, HiraiS, OzawaE (1993) Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects. J Neurol Sci 119: 43–52.

29. KleopaKA, DrousiotouA, MavrikiouE, OrmistonA, KyriakidesT (2006) Naturally occurring utrophin correlates with disease severity in Duchenne muscular dystrophy. Hum Mol Genet 15: 1623–1628.

30. VainzofM, Passos-BuenoMR, ManN, ZatzM (1995) Absence of correlation between utrophin localization and quantity and the clinical severity in Duchenne/Becker dystrophies. Am J Med Genet 58: 305–309.

31. TaylorJ, MuntoniF, DubowitzV, SewryCA (1997) The abnormal expression of utrophin in Duchenne and Becker muscular dystrophy is age related. Neuropathol Appl Neurobiol 23: 399–405.

32. FlaniganKM, CampbellK, ViolletL, WangW, GomezAM, et al. (2013) Anti-dystrophin T cell responses in Duchenne muscular dystrophy: prevalence and a glucocorticoid treatment effect. Hum Gene Ther 24: 797–806.

33. FaircloughRJ, WoodMJ, DaviesKE (2013) Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches. Nat Rev Genet 14: 373–378.

34. MuellerC, ChulayJD, TrapnellBC, HumphriesM, CareyB, et al. (2013) Human Treg responses allow sustained recombinant adeno-associated virus-mediated transgene expression. J Clin Invest 123: 5310–5318.

35. AmentaAR, YilmazA, BogdanovichS, McKechnieBA, AbediM, et al. (2011) Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. Proc Natl Acad Sci U S A 108: 762–767.

36. HelliwellTR, ManNT, MorrisGE, DaviesKE (1992) The dystrophin-related protein, utrophin, is expressed on the sarcolemma of regenerating human skeletal muscle fibres in dystrophies and inflammatory myopathies. Neuromuscul Disord 2: 177–184.

37. WeirAP, MorganJE, DaviesKE (2004) A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration. Neuromuscul Disord 14: 19–23.

38. LjubicicV, BurtM, JasminBJ (2013) The therapeutic potential of skeletal muscle plasticity in Duchenne muscular dystrophy: phenotypic modifiers as pharmacologic targets. FASEB J 28: 548–568.

39. MarshallJL, KwokY, McMorranBJ, BaumLG, Crosbie-WatsonRH (2013) The potential of sarcospan in adhesion complex replacement therapeutics for the treatment of muscular dystrophy. FEBS J 280: 4210–4229.

40. BanksGB, CombsAC, ChamberlainJR, ChamberlainJS (2008) Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Hum Mol Genet 17: 3975–3986.

41. BanksGB, JudgeLM, AllenJM, ChamberlainJS (2010) The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. PLoS Genet 6: e1000958.

42. LazaridesE, HubbardBD (1976) Immunological characterization of the subunit of the 100 A filaments from muscle cells. Proc Natl Acad Sci U S A 73: 4344–4348.

43. LazaridesE, BalzerDRJr (1978) Specificity of desmin to avian and mammalian muscle cells. Cell 14: 429–438.

44. LiZ, MericskayM, AgbulutO, Butler-BrowneG, CarlssonL, et al. (1997) Desmin is essential for the tensile strength and integrity of myofibrils but not for myogenic commitment, differentiation, and fusion of skeletal muscle. J Cell Biol 139: 129–144.

45. MilnerDJ, WeitzerG, TranD, BradleyA, CapetanakiY (1996) Disruption of muscle architecture and myocardial degeneration in mice lacking desmin. J Cell Biol 134: 1255–1270.

46. ErvastiJM (2003) Costameres: the Achilles' heel of Herculean muscle. J Biol Chem 278: 13591–13594.

47. O'NeillA, WilliamsMW, ResneckWG, MilnerDJ, CapetanakiY, et al. (2002) Sarcolemmal organization in skeletal muscle lacking desmin: evidence for cytokeratins associated with the membrane skeleton at costameres. Mol Biol Cell 13: 2347–2359.

48. LiZ, Colucci-GuyonE, Pincon-RaymondM, MericskayM, PourninS, et al. (1996) Cardiovascular lesions and skeletal myopathy in mice lacking desmin. Dev Biol 175: 362–366.

49. WildingJR, SchneiderJE, SangAE, DaviesKE, NeubauerS, et al. (2005) Dystrophin- and MLP-deficient mouse hearts: marked differences in morphology and function, but similar accumulation of cytoskeletal proteins. FASEB J 19: 79–81.

50. LewisC, OhlendieckK (2010) Proteomic profiling of naturally protected extraocular muscles from the dystrophin-deficient mdx mouse. Biochem Biophys Res Commun 396: 1024–1029.

51. ChamberlainJS, MetzgerJ, ReyesM, TownsendD, FaulknerJA (2007) Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 21: 2195–2204.

52. LoveringRM, O'NeillA, MurielJM, ProsserBL, StrongJ, et al. (2011) Physiology, structure, and susceptibility to injury of skeletal muscle in mice lacking keratin 19-based and desmin-based intermediate filaments. Am J Physiol Cell Physiol 300: C803–813.

53. OdomGL, GregorevicP, AllenJM, FinnE, ChamberlainJS (2008) Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol Ther 16: 1539–1545.

54. TakemitsuM, IshiuraS, KogaR, KamakuraK, ArahataK, et al. (1991) Dystrophin-related protein in the fetal and denervated skeletal muscles of normal and mdx mice. Biochem Biophys Res Commun 180: 1179–1186.

55. SewryCA, NowakKJ, EhmsenJT, DaviesKE (2005) A and B utrophin in human muscle and sarcolemmal A-utrophin associated with tumours. Neuromuscul Disord 15: 779–785.

56. LiH, CapetanakiY (1994) An E box in the desmin promoter cooperates with the E box and MEF-2 sites of a distal enhancer to direct muscle-specific transcription. EMBO J 13: 3580–3589.

57. WeitzerG, MilnerDJ, KimJU, BradleyA, CapetanakiY (1995) Cytoskeletal control of myogenesis: a desmin null mutation blocks the myogenic pathway during embryonic stem cell differentiation. Dev Biol 172: 422–439.

58. CapetanakiY, MilnerDJ, WeitzerG (1997) Desmin in muscle formation and maintenance: knockouts and consequences. Cell Struct Funct 22: 103–116.

59. AgbulutO, LiZ, PerieS, LudoskyMA, PaulinD, et al. (2001) Lack of desmin results in abortive muscle regeneration and modifications in synaptic structure. Cell Motil Cytoskeleton 49: 51–66.

60. KoniecznyP, FuchsP, ReipertS, KunzWS, ZeoldA, et al. (2008) Myofiber integrity depends on desmin network targeting to Z-disks and costameres via distinct plectin isoforms. J Cell Biol 181: 667–681.

61. OhlendieckK, CampbellKP (1991) Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. J Cell Biol 115: 1685–1694.

62. FongAP, TapscottSJ (2013) Skeletal muscle programming and re-programming. Curr Opin Genet Dev 23: 568–573.

63. RosenbergMI, GeorgesSA, AsawachaicharnA, AnalauE, TapscottSJ (2006) MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol 175: 77–85.

64. BasuU, LozynskaO, MoorwoodC, PatelG, WiltonSD, et al. (2011) Translational regulation of utrophin by miRNAs. PLoS One 6: e29376.

65. GramoliniAO, JasminBJ (1999) Expression of the utrophin gene during myogenic differentiation. Nucleic Acids Res 27: 3603–3609.

66. ShahSB, DavisJ, WeislederN, KostavassiliI, McCullochAD, et al. (2004) Structural and functional roles of desmin in mouse skeletal muscle during passive deformation. Biophys J 86: 2993–3008.

67. MarklundN, BareyreFM, RoyoNC, ThompsonHJ, MirAK, et al. (2007) Cognitive outcome following brain injury and treatment with an inhibitor of Nogo-A in association with an attenuated downregulation of hippocampal growth-associated protein-43 expression. J Neurosurg 107: 844–853.

68. VerganiL, GrattarolaM, NicoliniC (2004) Modifications of chromatin structure and gene expression following induced alterations of cellular shape. Int J Biochem Cell Biol 36: 1447–1461.

69. ChenCS, MrksichM, HuangS, WhitesidesGM, IngberDE (1997) Geometric control of cell life and death. Science 276: 1425–1428.

70. NikolovaV, LeimenaC, McMahonAC, TanJC, ChandarS, et al. (2004) Defects in nuclear structure and function promote dilated cardiomyopathy in lamin A/C-deficient mice. J Clin Invest 113: 357–369.

71. FavreB, SchneiderY, LingasamyP, BouameurJE, BegreN, et al. (2011) Plectin interacts with the rod domain of type III intermediate filament proteins desmin and vimentin. Eur J Cell Biol 90: 390–400.

72. KoniecznyP, WicheG (2008) Muscular integrity—a matter of interlinking distinct structures via plectin. Adv Exp Med Biol 642: 165–175.

73. GramoliniAO, BelangerG, ThompsonJM, ChakkalakalJV, JasminBJ (2001) Increased expression of utrophin in a slow vs. a fast muscle involves posttranscriptional events. Am J Physiol Cell Physiol 281: C1300–1309.

74. AngusLM, ChakkalakalJV, MejatA, EiblJK, BelangerG, et al. (2005) Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction. Am J Physiol Cell Physiol 289: C908–917.

75. HollingerK, Gardan-SalmonD, SantanaC, RiceD, SnellaE, et al. (2013) Rescue of dystrophic skeletal muscle by PGC-1alpha involves restored expression of dystrophin-associated protein complex components and satellite cell signaling. Am J Physiol Regul Integr Comp Physiol 305: R13–23.

76. SelsbyJT, MorineKJ, PendrakK, BartonER, SweeneyHL (2012) Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse. PLoS One 7: e30063.

77. ChakkalakalJV, StocksleyMA, HarrisonMA, AngusLM, Deschenes-FurryJ, et al. (2003) Expression of utrophin A mRNA correlates with the oxidative capacity of skeletal muscle fiber types and is regulated by calcineurin/NFAT signaling. Proc Natl Acad Sci U S A 100: 7791–7796.

78. ChakkalakalJV, HarrisonMA, CarbonettoS, ChinE, MichelRN, et al. (2004) Stimulation of calcineurin signaling attenuates the dystrophic pathology in mdx mice. Hum Mol Genet 13: 379–388.

79. St-PierreSJ, ChakkalakalJV, KolodziejczykSM, KnudsonJC, JasminBJ, et al. (2004) Glucocorticoid treatment alleviates dystrophic myofiber pathology by activation of the calcineurin/NF-AT pathway. FASEB J 18: 1937–1939.

80. StupkaN, SchertzerJD, Bassel-DubyR, OlsonEN, LynchGS (2007) Calcineurin-A alpha activation enhances the structure and function of regenerating muscles after myotoxic injury. Am J Physiol Regul Integr Comp Physiol 293: R686–694.

81. MichelRN, ChinER, ChakkalakalJV, EiblJK, JasminBJ (2007) Ca2+/calmodulin-based signalling in the regulation of the muscle fibre phenotype and its therapeutic potential via modulation of utrophin A and myostatin expression. Appl Physiol Nutr Metab 32: 921–929.

82. LjubicicV, MiuraP, BurtM, BoudreaultL, KhogaliS, et al. (2011) Chronic AMPK activation evokes the slow, oxidative myogenic program and triggers beneficial adaptations in mdx mouse skeletal muscle. Hum Mol Genet 20: 3478–3493.

83. MiuraP, ChakkalakalJV, BoudreaultL, BelangerG, HebertRL, et al. (2009) Pharmacological activation of PPARbeta/delta stimulates utrophin A expression in skeletal muscle fibers and restores sarcolemmal integrity in mature mdx mice. Hum Mol Genet 18: 4640–4649.

84. MiuraP, AndrewsM, HolcikM, JasminBJ (2008) IRES-mediated translation of utrophin A is enhanced by glucocorticoid treatment in skeletal muscle cells. PLoS One 3: e2309.

85. MeyerGA, LieberRL (2012) Skeletal muscle fibrosis develops in response to desmin deletion. Am J Physiol Cell Physiol 302: C1609–1620.

86. MeyerGA, SchenkS, LieberRL (2013) Role of the cytoskeleton in muscle transcriptional responses to altered use. Physiol Genomics 45: 321–331.

87. PriceMG, LazaridesE (1983) Expression of intermediate filament-associated proteins paranemin and synemin in chicken development. J Cell Biol 97: 1860–1874.

88. BellinRM, SernettSW, BeckerB, IpW, HuiattTW, et al. (1999) Molecular characteristics and interactions of the intermediate filament protein synemin. Interactions with alpha-actinin may anchor synemin-containing heterofilaments. J Biol Chem 274: 29493–29499.

89. RussellMA, LundLM, HaberR, McKeeganK, CianciolaN, et al. (2006) The intermediate filament protein, synemin, is an AKAP in the heart. Arch Biochem Biophys 456: 204–215.

90. OzawaT (2010) Modulation of ryanodine receptor Ca2+ channels (Review). Mol Med Rep 3: 199–204.

91. DanilaCI, HamiltonSL (2004) Phosphorylation of ryanodine receptors. Biol Res 37: 521–525.

92. FullerMD, EmrickMA, SadilekM, ScheuerT, CatterallWA (2010) Molecular mechanism of calcium channel regulation in the fight-or-flight response. Sci Signal 3: ra70.

93. GramoliniAO, TrivieriMG, OuditGY, KislingerT, LiW, et al. (2006) Cardiac-specific overexpression of sarcolipin in phospholamban null mice impairs myocyte function that is restored by phosphorylation. Proc Natl Acad Sci U S A 103: 2446–2451.

94. PeterAK, MarshallJL, CrosbieRH (2008) Sarcospan reduces dystrophic pathology: stabilization of the utrophin-glycoprotein complex. J Cell Biol 183: 419–427.

95. MarshallJL, HolmbergJ, ChouE, OcampoAC, OhJ, et al. (2012) Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration. J Cell Biol 197: 1009–1027.

96. NguyenHH, JayasinhaV, XiaB, HoyteK, MartinPT (2002) Overexpression of the cytotoxic T cell GalNAc transferase in skeletal muscle inhibits muscular dystrophy in mdx mice. Proc Natl Acad Sci U S A 99: 5616–5621.

97. Gauthier-RouviereC, Bonet-KerracheA (2009) RhoA leads to up-regulation and relocalization of utrophin in muscle fibers. Biochem Biophys Res Commun 384: 322–328.

98. ChallaAA, StefanovicB (2011) A novel role of vimentin filaments: binding and stabilization of collagen mRNAs. Mol Cell Biol 31: 3773–3789.

99. MoorwoodC, SoniN, PatelG, WiltonSD, KhuranaTS (2013) A cell-based high-throughput screening assay for posttranscriptional utrophin upregulation. J Biomol Screen 18: 400–406.

100. ChakkalakalJV, MiuraP, BelangerG, MichelRN, JasminBJ (2008) Modulation of utrophin A mRNA stability in fast versus slow muscles via an AU-rich element and calcineurin signaling. Nucleic Acids Res 36: 826–838.

101. CapetanakiY, BlochRJ, KouloumentaA, MavroidisM, PsarrasS (2007) Muscle intermediate filaments and their links to membranes and membranous organelles. Exp Cell Res 313: 2063–2076.

102. LiW, ZhangQ, OisoN, NovakEK, GautamR, et al. (2003) Hermansky-Pudlak syndrome type 7 (HPS-7) results from mutant dysbindin, a member of the biogenesis of lysosome-related organelles complex 1 (BLOC-1). Nat Genet 35: 84–89.

103. RafaelJA, TinsleyJM, PotterAC, DeconinckAE, DaviesKE (1998) Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice. Nat Genet 19: 79–82.

104. SonnemannKJ, Heun-JohnsonH, TurnerAJ, BaltgalvisKA, LoweDA, et al. (2009) Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med 6: e1000083.

105. MercadoML, AmentaAR, HagiwaraH, RafiiMS, LechnerBE, et al. (2006) Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. FASEB J 20: 1724–1726.

106. LiD, BarejaA, JudgeL, YueY, LaiY, et al. (2010) Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. J Cell Sci 123: 2008–2013.

107. EnglandSB, NicholsonLV, JohnsonMA, ForrestSM, LoveDR, et al. (1990) Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 343: 180–182.

108. AlbrechtDE, FroehnerSC (2002) Syntrophins and dystrobrevins: defining the dystrophin scaffold at synapses. Neurosignals 11: 123–129.

109. AdamsME, MuellerHA, FroehnerSC (2001) In vivo requirement of the alpha-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4. J Cell Biol 155: 113–122.

110. ShahSB, LoveJM, O'NeillA, LoveringRM, BlochRJ (2012) Influences of desmin and keratin 19 on passive biomechanical properties of mouse skeletal muscle. J Biomed Biotechnol 2012: 704061.

111. Kornegay JN, Childers MK, Bogan DJ, Bogan JR, Nghiem P, et al.. (2012) The paradox of muscle hypertrophy in muscular dystrophy. Phys Med Rehabil Clin N Am 23: 149–172, xii.

112. BanksGB, CombsAC, ChamberlainJS (2010) Sequencing protocols to genotype mdx, mdx(4cv), and mdx(5cv) mice. Muscle Nerve 42: 268–270.

113. GregorevicP, AllenJM, MinamiE, BlankinshipMJ, HaraguchiM, et al. (2006) rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12: 787–789.

114. BanksGB, ChamberlainJS, FroehnerSC (2009) Truncated dystrophins can influence neuromuscular synapse structure. Mol Cell Neurosci 40: 433–441.

115. GregorevicP, MeznarichNA, BlankinshipMJ, CrawfordRW, ChamberlainJS (2008) Fluorophore-labeled myosin-specific antibodies simplify muscle-fiber phenotyping. Muscle Nerve 37: 104–106.

116. BanksGB, GregorevicP, AllenJM, FinnEE, ChamberlainJS (2007) Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Hum Mol Genet 16: 2105–2113.

117. HanftLM, RybakovaIN, PatelJR, Rafael-FortneyJA, ErvastiJM (2006) Cytoplasmic gamma-actin contributes to a compensatory remodeling response in dystrophin-deficient muscle. Proc Natl Acad Sci U S A 103: 5385–5390.

118. GubernC, HurtadoO, RodriguezR, MoralesJR, RomeraVG, et al. (2009) Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia. BMC Mol Biol 10: 57.